Simeprevir and VX-135 Team Up in Phase II Hep C Trial

Share

Follow Us

Print this page

Phase II All-oral Study Of Simeprevir And VX-135 For The Treatment Of Hepatitis C

By News Staff | November 3rd 2012

Medivir AB has announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a drug-drug interaction study with simeprevir and VX-135 to support the planned initiation of a phase II proof-of-concept study in early 2013, pending discussions with regulatory authorities.

The phase II study is expected to evaluate safety, tolerability and viral cure rates using a 12-week combination of simeprevir and VX-135, with and without ribavirin. Janssen and Vertex will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Continue reading this entire article:
http://www.science20.com/news_articles/phase_ii_alloral_study_simeprevir_and_vx135_treatment_hepatitis_c-95931

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.